WESPAC Advisors SoCal’s Anixa Biosciences ANIX Stock Holding History

WESPAC Advisors SoCal’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-40	Closed	–	–	289
2015 Q4	$0	Buy	+40	New	+$140	﹤0.01%	257

Other funds holding ANIX

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

DIA

Denver Investment Advisors Denver, Colorado $1.89B AUM 7.9% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WESPAC Advisors SoCal's ANIX Position: Q1 2016 in Review

WESPAC Advisors SoCal sold out of Anixa Biosciences (ANIX) in Q1 2016, closing a stake of 40 shares.

WESPAC Advisors SoCal first reported a position in ANIX in Q4 2015 and held it in 1 quarter. The position peaked at $0 in Q4 2015. 15 funds tracked by Wall St. Rank hold ANIX as of Q1 2016.

WESPAC Advisors SoCal reported no remaining Anixa Biosciences position as of Q1 2016 after selling out during the quarter.
WESPAC Advisors SoCal sold 40 Anixa Biosciences shares in Q1 2016.
WESPAC Advisors SoCal first reported a position in Anixa Biosciences in Q4 2015 and held it in 1 quarter.
WESPAC Advisors SoCal's Anixa Biosciences position peaked at $0 in Q4 2015.
15 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2016.

Based on WESPAC Advisors SoCal's 13F filing for Q1 2016, filed 12 Aug 2016.